-
公开(公告)号：US11028399B2
公开(公告)日：2021-06-08
申请号：US16443973
申请日：2019-06-18
申请人： BIOCON LIMITED
IPC分类号： C07K14/00 , A61K39/395 , C07K7/08 , A61K39/00 , C12N15/62 , C07K14/495 , C07K14/65 , C07K14/705 , C07K16/28 , C07K16/32 , G01N33/68 , A61K38/10 , A61K38/17 , A61K45/06 , C07K14/71 , C07K16/30 , A61K48/00 , C12N5/00 , A61K38/00
摘要： The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
-
公开(公告)号：US11060097B2
公开(公告)日：2021-07-13
申请号：US16263157
申请日：2019-01-31
申请人： BIOCON LIMITED
IPC分类号： C07K16/28 , C07K14/705 , C07K14/495 , C07K14/71 , C07K14/00 , A61K39/395 , A61K38/17 , C12N15/62 , G01N33/68 , C07K16/32 , C07K14/65 , C07K7/08 , A61K48/00 , C07K16/30 , A61K38/10 , A61K45/06 , C12N5/00 , A61K39/00 , A61K38/00
摘要： The present invention provides for a composition and a method for treating a subject afflicted with a cancer, wherein the composition comprises therapeutically effective amounts of: (a) an anti-Programmed Death-Ligand 1 (PD-L1) antibody and (b) a targeted/immunomodulatory fusion protein comprising at least one tumor targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
-
公开(公告)号：US09340617B2
公开(公告)日：2016-05-17
申请号：US14458674
申请日：2014-08-13
申请人： BIOCON LIMITED
IPC分类号： C07K14/00 , C07K16/28 , C07K14/495 , C07K16/32 , C07K14/65 , C07K14/705 , G01N33/68
CPC分类号： C12N15/62 , A61K38/00 , A61K38/10 , A61K38/179 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K48/005 , A61K2039/505 , A61K2121/00 , C07K7/08 , C07K14/00 , C07K14/495 , C07K14/65 , C07K14/70532 , C07K14/70596 , C07K14/71 , C07K16/2818 , C07K16/2863 , C07K16/2866 , C07K16/2878 , C07K16/2887 , C07K16/30 , C07K16/32 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/732 , C07K2319/00 , C07K2319/02 , C07K2319/33 , C12N5/0018 , C12N2500/22 , G01N33/6854
摘要： The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
摘要翻译： 本发明一般涉及产生用于癌症治疗的融合蛋白的领域，更具体地，涉及编码融合蛋白的核苷酸序列，其中所述嵌合融合蛋白包含至少一个靶向部分和至少一个抵抗的免疫调节部分 癌细胞的免疫耐受。
-
公开(公告)号：US09862958B2
公开(公告)日：2018-01-09
申请号：US14434595
申请日：2012-12-05
申请人： Biocon Limited
发明人： Nagaraj Govindappa , Sankar Periyasamy , Shivakumar Madenahalli Channabasappa , Suma Sreenivas , Kedamath Nanjund Sastry
CPC分类号： C12N15/815 , C07K14/76 , C07K14/811 , C12N9/0006 , C12P19/34 , C12P21/00 , C12P21/02 , C12Y101/01014
摘要： The present disclosure relates to a process of identification and isolation of sorbitol dehydrogenase promoter from Pichia pastoris. Further, the present disclosure also relates to expression of heterologous proteins under the control of Sorbitol dehydrogenase promoter in Pichia pastoris.
-
公开(公告)号：US08815247B2
公开(公告)日：2014-08-26
申请号：US13799409
申请日：2013-03-13
申请人： Biocon Limited
IPC分类号： A61K39/00
CPC分类号： C12N15/62 , A61K38/00 , A61K38/10 , A61K38/179 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K48/005 , A61K2039/505 , A61K2121/00 , C07K7/08 , C07K14/00 , C07K14/495 , C07K14/65 , C07K14/70532 , C07K14/70596 , C07K14/71 , C07K16/2818 , C07K16/2863 , C07K16/2866 , C07K16/2878 , C07K16/2887 , C07K16/30 , C07K16/32 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/732 , C07K2319/00 , C07K2319/02 , C07K2319/33 , C12N5/0018 , C12N2500/22 , G01N33/6854
摘要： The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
摘要翻译： 本发明一般涉及产生用于癌症治疗的融合蛋白的领域，更具体地，涉及编码融合蛋白的核苷酸序列，其中所述嵌合融合蛋白包含至少一个靶向部分和至少一个抵抗的免疫调节部分 癌细胞的免疫耐受。
-
公开(公告)号：US12049632B2
公开(公告)日：2024-07-30
申请号：US17339112
申请日：2021-06-04
申请人： BIOCON LIMITED
IPC分类号： C07K14/705 , A61K38/00 , A61K38/10 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/06 , A61K48/00 , C07K7/08 , C07K14/00 , C07K14/495 , C07K14/65 , C07K14/71 , C07K16/28 , C07K16/30 , C07K16/32 , C12N5/00 , C12N15/62 , G01N33/68
CPC分类号： C12N15/62 , A61K38/10 , A61K38/179 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K48/005 , C07K7/08 , C07K14/00 , C07K14/495 , C07K14/65 , C07K14/70532 , C07K14/70596 , C07K14/71 , C07K16/2818 , C07K16/2863 , C07K16/2866 , C07K16/2878 , C07K16/2887 , C07K16/30 , C07K16/32 , C12N5/0018 , G01N33/6854 , A61K38/00 , A61K2039/505 , A61K2121/00 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/732 , C07K2319/00 , C07K2319/02 , C07K2319/33 , C12N2500/22
摘要： The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
-
公开(公告)号：US10385348B2
公开(公告)日：2019-08-20
申请号：US15795404
申请日：2017-10-27
申请人： BIOCON LIMITED
IPC分类号： C07K14/00 , C07K14/495 , C07K16/32 , G01N33/68 , A61K38/10 , A61K38/17 , A61K39/395 , A61K45/06 , C07K7/08 , C07K14/71 , C07K16/30 , A61K48/00 , A61K39/00 , A61K38/00 , C12N15/62 , C07K14/65 , C07K14/705 , C07K16/28 , C12N5/00
摘要： The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
-
公开(公告)号：US09758582B2
公开(公告)日：2017-09-12
申请号：US15145135
申请日：2016-05-03
申请人： BIOCON LIMITED
IPC分类号： C07K16/28 , A61K38/10 , A61K38/18 , A61K39/395 , C07K14/495 , C07K14/00 , C07K14/65 , C07K14/705 , C07K16/32 , G01N33/68 , A61K38/17 , A61K45/06 , C07K7/08 , C07K14/71 , C07K16/30 , A61K39/00 , A61K38/00
CPC分类号： C12N15/62 , A61K38/00 , A61K38/10 , A61K38/179 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K48/005 , A61K2039/505 , A61K2121/00 , C07K7/08 , C07K14/00 , C07K14/495 , C07K14/65 , C07K14/70532 , C07K14/70596 , C07K14/71 , C07K16/2818 , C07K16/2863 , C07K16/2866 , C07K16/2878 , C07K16/2887 , C07K16/30 , C07K16/32 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/732 , C07K2319/00 , C07K2319/02 , C07K2319/33 , C12N5/0018 , C12N2500/22 , G01N33/6854
摘要： The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
-
公开(公告)号：US20150284731A1
公开(公告)日：2015-10-08
申请号：US14434595
申请日：2012-12-05
申请人： BIOCON LIMITED
发明人： Nagaraj Govindappa , Sankar Periyasamy , Shivakumar Madenahalli Channabasappa , Suma Sreenivas , Kedamath Nanjund Sastry
CPC分类号： C12N15/815 , C07K14/76 , C07K14/811 , C12N9/0006 , C12P19/34 , C12P21/00 , C12P21/02 , C12Y101/01014
摘要： The present disclosure relates to a process of identification and isolation of sorbitol dehydrogenase promoter from Pichia pastoris. Further, the present disclosure also relates to expression of heterologous proteins under the control of Sorbitol dehydrogenase promoter in Pichia pastoris.
摘要翻译： 本公开涉及从巴斯德毕赤酵母中鉴定和分离山梨醇脱氢酶启动子的方法。 此外，本公开还涉及在巴斯德毕赤酵母中在山梨糖醇脱氢酶启动子控制下的异源蛋白质的表达。
-
公开(公告)号：US10144934B2
公开(公告)日：2018-12-04
申请号：US15444527
申请日：2017-02-28
申请人： BIOCON LIMITED
IPC分类号： C07K7/08 , C07K14/00 , C07K14/71 , C07K16/28 , C07K16/30 , C07K16/32 , C07K14/495 , C07K14/705 , C12N5/00 , C12N15/62 , A61K38/17 , A61K39/00 , A61K39/395 , C07K14/65 , G01N33/68 , A61K38/10 , A61K45/06 , A61K48/00 , A61K38/00
摘要： The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.033 秒)
